In addition, recent research has shown that targeting the CD6/CD318 axis with the mAb UMCD6 (anti-CD6) increases cytotoxic-lymphocyte-mediated cancer cell death of breast, prostate, and lung cancers both in vitro and in vivo [39,50]. Here, CD6 is linked to lung carcinoma.